BEDFORD, Mass.--(BUSINESS WIRE)--May 3, 2016--
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye, today announced that it will
report first quarter 2016 financial results on Tuesday, May 10, 2016.
Following distribution of the earnings release via wire services, the
Ocular Therapeutix management team will host a live conference call and
webcast at 8:00 a.m. Eastern Time to review the Company's financial
results and provide a business update.
The live webcast can be accessed by visiting the Investors section of
the Company’s website at investors.ocutx.com.
Please connect at least 15 minutes prior to the live webcast to ensure
adequate time for any software download that may be needed to access the
webcast. Alternatively, please call 844-464-3934 (U.S.) or 765-507-2620
(International) to listen to the conference call. The conference ID
number for the live call will be 3038508. An archive of the webcast will
be available until May 24, 2016 on the Company’s website.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary hydrogel
platform technology. Ocular Therapeutix's lead product candidate,
DEXTENZA™ (sustained release dexamethasone) Intracanalicular Depot, is
in Phase 3 clinical development for post-surgical ocular inflammation
and pain and allergic conjunctivitis, and in Phase 2 clinical
development for dry eye disease. A New Drug Application (NDA) for the
post-operative ocular pain indication has been filed with FDA and has a
Prescription Drug User Fee Act (PDUFA) target action date of July 24,
2016. A third Phase 3 clinical trial is being conducted for
post-surgical ocular inflammation and pain. For glaucoma and ocular
hypertension, the Company has completed its End-of-Phase 2 review with
the FDA, and the first of two planned OTX-TP Phase 3 clinical trials is
expected to be initiated in the third quarter of 2016. Ocular
Therapeutix is also evaluating sustained-release injectable anti-VEGF
drug depots for back-of-the-eye diseases. Ocular Therapeutix's first
product, ReSure® Sealant, is FDA-approved to seal corneal
incisions following cataract surgery.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160503006434/en/
Source: Ocular Therapeutix, Inc.
Investors
Ocular Therapeutix, Inc.
Brad Smith
Chief
Financial Officer
bsmith@ocutx.com
or
Burns
McClellan on behalf of Ocular Therapeutix
Steve Klass, 212-213-0006
sklass@burnsmc.com
or
Media
Ocular
Therapeutix, Inc.
Scott Corning
Vice President of Sales and
Marketing
scorning@ocutx.com